ArticleEuropean journal of nuclear medicine and molecular imaging2020
Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison.European journal of nuclear medicine and molecular imaging · 2021Trial
- Exploring the associations between lifestyle and dietary patterns with preclinical alzheimer's disease: findings from La Rioja cohort study.European journal of nutrition · 2026Article
- Lecanemab approval in EU: what should we be ready for?- the EANM perspective.European journal of nuclear medicine and molecular imaging · 2025Article
- Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Incremental value of amyloid PET in a tertiary memory clinic setting in China.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease.International journal of molecular sciences · 2023Review
- The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.Journal of Alzheimer's disease : JAD · 2022Article
- Differential Clearance of Aβ Species from the Brain by Brain Lymphatic Endothelial Cells in Zebrafish.International journal of molecular sciences · 2021Article
- Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity.Molecular psychiatry · 2021Article
- The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community.European journal of nuclear medicine and molecular imaging · 2021Article
- Molecular imaging and fluid biomarkers of Alzheimer's disease neuropathology: an opportunity for integrated diagnostics.European journal of nuclear medicine and molecular imaging · 2021Article
- The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease.International journal of molecular sciences · 2021Review
- Clinical Relevance of [Molecules (Basel, Switzerland) · 2021Article
- Clinical impact ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia.Journal of personalized medicine · 2021Article
- Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity.Clinical interventions in aging · 2021Observational
- Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer's dementia: a comparison of methods.Alzheimer's research & therapy · 2020Article
- Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 11 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm.
methodsTwo independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker.
resultsAmong patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P < 0.001); PET induced a diagnostic confidence increase significantly higher than CSF on both rounds 2 and 3.
conclusionsAmyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence.
trial registrationEudraCT no.: 2014-005389-31.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.